Wells Fargo
CRSP icon

Wells Fargo’s CRISPR Therapeutics CRSP Stock Holding History

Wells Fargo’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$5.24K – 7232
2025
Q4 		$5.24K Hold
100
– – ﹤0.01% 6087
2025
Q3 		$6.48K Hold
100
– – ﹤0.01% 6029
2025
Q2 		$4.86K Buy
+100
New +$3.87K ﹤0.01% 6094

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo's CRSP Position: Q1 2026 in Review

Wells Fargo reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, selling an estimated $2.01M and leaving 280,709 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Wells Fargo first reported a position in CRSP in Q4 2016 and has held it in 38 quarters since. The position peaked at $75.5M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Wells Fargo held 280,709 shares of CRISPR Therapeutics worth $13.4M as of Q1 2026.
  • Wells Fargo sold 38,169 CRISPR Therapeutics shares in Q1 2026, an estimated $2.01M.
  • CRISPR Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1814 holding.
  • Wells Fargo first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • Wells Fargo's CRISPR Therapeutics position peaked at $75.5M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.